Abstract 567P
Background
Leptomeningeal metastasis (LM) is one of the most severe complications of non-small cell lung cancer (NSCLC) and is always accompanied by poor prognosis. The optimal treatment for EGFR–mutated NSCLC patients with LM after EGFR-TKI therapy failure remains unclear. Furmonertinib is a novel third-generation EGFR-TKI. A phase I-II dose-expansion study (NCT03127449) suggested that furmonertinib had a favorable antitumor activity with a wide therapeutic range and minimal toxicity. This retrospective study aimed to evaluate the efficacy and safety of furmonertinib 160mg in combination with bevacizumab and intrathecal chemotherapy in EGFR-mutated NSCLC patients with LM after initial TKI failure in the real world.
Methods
We retrospectively studied 19 NSCLC pts with LM treated with furmonertinib in combination with bevacizumab and intrathecal chemotherapy between February 2021 and April 2023 at Nanjing Chest Hospital. All of them received third-generation EGFR TKIs-based therapies previously. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), and toxicity were assessed.
Results
The median age was 57 years (range: 31-77), 6 (31.6%) were males and 13 (68.4%) were females. 4 (21.1%) had EOCG 2, 7 (36.8%) had ECOG 3, and 8 (42.1%) had ECOG 4. 16 patients (84.2%) had partial remission (PR) of LM lesions, 3 patients (15.8%) had stable disease (SD). The intracranial ORR (iORR) was 84.2% and intracranial DCR (iDCR) was 100%. 5 patients achieved PR and 14 patients had SD in the whole lesion, ORR was 26.3% and DCR was 100%. Median PFS was 11.9 months (95% CI 2.8–21.0). The overall survival data were not mature (the overall maturity was 26%). Treatment-related adverse events of ≥ grade 3 occurred in only 1 (5.3%) of 19 patients. Safety profile consistent with previous studies of furmonertinib.
Conclusions
Rechallenges of furmonertinib in combination with bevacizumab and intrathecal chemotherapy has shown significant efficacy and tolerable safety profile in EGFR–mutated NSCLC patients with LM after third-generation EGFR-TKIs treatment failure. The further exploration is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract